.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the symbol “BIOA,” according to papers filed along with the Stocks as well as Exchange Payment. The firm has certainly not openly shared an anticipated monetary volume for the offering.The clinical-stage provider proclaims lead prospect azelaprag, a by mouth supplied little molecule slated to enter into stage 2 screening in combination with semaglutide– offered by Novo Nordisk under brand Wegovy for effective weight loss– in the first one-half of following year. Semaglutide is likewise marketed as Ozempic as well as Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is made to blend effectively along with GLP-1 medicines, increasing weight loss while maintaining muscle mass. The investigational medication was found to become well-tolerated amongst 265 individuals across 8 stage 1 trials, according to BioAge.Earlier, BioAge gathered the assistance of Lilly to operate a trial mixing azelaprag along with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro and also Zepbound for weight-loss. The partners are actually currently conducting a stage 2 test of azelaprag and also tirzepatide, along with topline outcomes expected in the 3rd quarter of 2025.The biotech is actually additionally organizing an insulin sensitivity proof-of-concept test examining azelaprag as a monotherapy in the 1st fifty percent of upcoming year to support possible sign expansion.
In addition, the firm plans to inquire the FDA for authorization in the second half of 2025 to introduce human screening for an NLRP3 prevention targeting metabolic health conditions and neuroinflammation.BioAge’s expected move to the public market follows a mild uptick in intended biotech IPOs coming from Bicara Rehabs and also Zenas Biopharma. Zooming out, the current IPO landscape is actually a “blended picture,” along with top notch companies still debuting on the public markets, just in decreased numbers, depending on to PitchBook.